Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801303 | 0.88 | ROCK2 (0.37) | ROCK2PARP1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1800564 | 0.87 | POLB (0.42) | ROCK2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL1801238 | 0.82 | POLB (0.41) | ROCK2POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL1802810 | 0.79 | POLB (0.38) | ROCK2POLBHTTALDH1A1KMT2A | |
| SCHEMBL1802453 | 0.69 | ALDH1A1 (0.39) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1803218 | 0.68 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1TDP1 | |
| SCHEMBL1801453 | 0.68 | MEN1 (0.37) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1800547 | 0.68 | TDP1 (0.47) | POLBALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1808204 | 0.67 | AVPR1A (0.46) | POLBHTTALDH1A1KMT2AMEN1 | |
| SCHEMBL1802983 | 0.67 | ALDH1A1 (0.41) | POLBALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | ROCK2 4597/4885PARP1 340/4885POLB 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.